Three-Dimensional Printed Plate-Guided 125I Brachytherapy for Malignant Parotid Tumors

Publication date: October 2018

Source: Journal of Oral and Maxillofacial Surgery, Volume 76, Issue 10

Author(s): Jinyuan Liu, Tianfu Wu, Qiwen Man, Nyimi Bushabu Fidèle, Yueyu Zheng, Bing Liu

Purpose

The treatment of malignant parotid tumors with ¹²⁵I brachytherapy is rarely reported. This study evaluated the efficacy and dose and response of ¹²⁵I brachytherapy in patients with malignant tumors.

Materials and Methods

From July 2014 through August 2017, 39 patients with malignant parotid tumors were treated with ¹²⁵I brachytherapy. Thirty-five patients were treated with conservative surgical resection before brachytherapy. Four patients were treated with brachytherapy alone. Clinical outcomes and side effects were evaluated. Clinical factors were investigated to determine correlations with local control (LC) and side effects.

Results

Mean follow-up was 25 months (range, 7 to 47 months). The LC rate was 87.2% and the overall survival rate was 97.4%. High tumor grade and large tumor showed a propensity for local recurrence. Acute skin toxicity occurred in 87.2% of patients and grade 3 and 4 radioepidermitis was found in 20.5% of patients. In total, 89.7% of patients with facial nerve dysfunction recovered within 12 months.

Conclusions

¹²⁵I brachytherapy was a feasible treatment option for patients with malignant parotid tumors. Although side effects were minimal, strict follow-up was necessary for patients treated with a high dose.

https://ift.tt/2Dv00oJ